Agonistas del receptor de GLP-1 (liraglutida, dulaglutida y semaglutida): aumentan el riesgo de duplicar el mecanismo de accin, lo que puede incrementar los efectos adversos (sobre todo gastrointestinales) sin un beneficio proporcional
Key preclinical findings included: Dose-dependent weight loss exceeding that of single- or dual-receptor agonists Improved glucose tolerance and insulin sensitivity Increased energy expenditure attributable to the glucagon receptor component Reduced hepatic steatosis Acceptable preclinical safety and toxicology profile These data supported an Investigational New Drug (IND) application to the FDA, enabling the transition to human clinical testing
Most of the side effects are gastrointestinal and might include feelings of early fullness, not having enough appetite, nausea, vomiting, and diarrhea
These 3 mechanisms create powerful synergy: significant fat loss while preserving lean muscle, improved glycemic control, and reduced appetite
Among various other factors, the growing obesity epidemic across the globe has also been associated with several debilitating disorders and diseases such as type 2 diabetes, visceral insulin resistance, and nonalcoholic fatty liver disease (NAFLD), among others [4,5,6,7]
Tirzepatide, the active ingredient, works by mimicking two naturally occurring hormones in your body GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)